M&A 2019 Mid-Year review for China pharmaceutical and medical device sector

Sep 2019

PwC recently launched M&A 1H2019 review - China pharmaceuticals and medical devices sectors which reviews numerous M&A data and cases in the pharmaceutical and medical device industry in 2019. In general, China pharmaceutical M&A was relatively active, and the volume and value are both increased. Meanwhile, the deal value of China medical device M&A decreased significantly, which were the lowest during the past 5 years.

Pharmaceutical sector 

China pharmaceutical M&A was relatively active in 1H19, with a 35% increase in deal volume and a 45% increase in deal value at US$10.8 billion. Overall deal volume reached 242, close to the highest seen in 1H18 (258), with activities from domestic strategic buyer almost doubled from 2H18.

Download the report

Medical device sector 

China medical device M&A in 1H19 decreased by 89% to merely $769m, which were the lowest during the past 5 years. No mega deals were conducted by domestic strategic buyer or PE while outbound deal almost froze. The volume of domestic strategic M&A increased by 33% but the value decreased by 43% to $615m, there were only 3 deals with value over $100m.

Download the report

Contact us

Xun Tang

China Central Transaction Services Leader, PwC China

Tel: +[86] (21) 2323 3396

Janelle Fei

Partner, PwC China

Tel: +[86] (21) 2323 5229

Follow us